Last edition
News about "immunotherapy"
Sobi Presents Positive Phase IIa Data for Gamifant in Interferon-Driven Sepsis
Sobi reports encouraging Phase IIa EMBRACE study results showing potential of Gamifant in interferon-gamma-driven sepsis, supporting precision medicine approaches in treating high-risk patients.
Immunotherapy | 19/03/2026 | By News Bureau
A multi-institutional study published in the Journal for ImmunoTherapy of Cancer finds that an AI-based imaging biomarker can predict immunotherapy outcomes and detect early treatment response in lung cancer patients.
Immunotherapy | 11/03/2026 | By News Bureau
Jiahui International Cancer Centre in Shanghai treats a US patient with advanced Non?Small Cell Lung Cancer using Ivonescimab, an experimental immunotherapy currently available only in China.
Immunotherapy | 09/03/2026 | By News Bureau
The FDA has granted Priority Review to Datroway for first-line treatment of metastatic triple-negative breast cancer patients ineligible for immunotherapy, with a regulatory decision expected in Q2 2026.
Immunotherapy | 04/02/2026 | By News Bureau | 133
Immorta Bio Reports Tumour Reduction Across Multiple Cancer Models with SenoVax
Immorta Bio has reported promising pre-clinical results showing that its anti-aging vaccine, SenoVax, reduced tumours across multiple validated cancer models. Developed in collaboration with academic institutions, the platform aims to dismantle tumour defense mechanisms and offer a non-toxic, longevity-driven approach to cancer treatment.
Immunotherapy | 05/12/2025 | By Dineshwori | 522
Greenwich LifeSciences Expands Flamingo-01 Breast Cancer Trial to Ireland
Greenwich LifeSciences has expanded its Phase III clinical trial, FLAMINGO-01, evaluating GLSI-100, an immunotherapy aimed at preventing breast cancer recurrences, to Ireland.
Immunotherapy | 18/09/2025 | By Dineshwori | 144
Cantargia Secures US Patent for Nadunolimab in Cancer Combination Therapies
Cantargia has announced that the United States Patent and Trademark Office (USPTO) has granted a new patent covering its antibody, nadunolimab.
Immunotherapy | 27/08/2025 | By Dineshwori | 231
GSK Enters Oncology in India with Launch of Jemperli and Zejula for Gynaecological Cancers
GSK has launched its much-awaited advanced therapies Jemperli (dostarlimab) and Zejula (niraparib) in India, reinforcing its commitment to addressing the unmet need for gynaecological cancers in the country.
Immunotherapy | 25/08/2025 | By Dineshwori | 308
Innovent Secures Fast Track Designation from FDA for IBI363
Innovent Biologics has announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation to its PD-1/IL-2α Bispecific Antibody Fusion Protein for the treatment of unresectable locally advanced or metastatic melanoma.
Immunotherapy | 04/09/2024 | By Aishwarya | 644
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy